Loading...

Sorrento Therapeutics

DB:8STN
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
8STN
DB
$440M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. The last earnings update was 35 days ago. More info.


Add to Portfolio Compare Print
  • Sorrento Therapeutics has significant price volatility in the past 3 months.
8STN Share Price and Events
7 Day Returns
-1.2%
DB:8STN
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-28.1%
DB:8STN
-10.6%
DE Biotechs
-6.2%
DE Market
8STN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sorrento Therapeutics (8STN) -1.2% 13.6% 80.8% -28.1% -42.8% -50.9%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • 8STN underperformed the Biotechs industry which returned -10.6% over the past year.
  • 8STN underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
8STN
Industry
5yr Volatility vs Market
Related Companies

8STN Value

 Is Sorrento Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Sorrento Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €3.543.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sorrento Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sorrento Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:8STN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.92
NasdaqCM:SRNE Share Price ** NasdaqCM (2019-04-18) in USD $3.84
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sorrento Therapeutics.

DB:8STN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:SRNE Share Price ÷ EPS (both in USD)

= 3.84 ÷ -1.92

-2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sorrento Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Sorrento Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Sorrento Therapeutics's expected growth come at a high price?
Raw Data
DB:8STN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts
47.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sorrento Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sorrento Therapeutics's assets?
Raw Data
DB:8STN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.83
NasdaqCM:SRNE Share Price * NasdaqCM (2019-04-18) in USD $3.84
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:8STN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:SRNE Share Price ÷ Book Value per Share (both in USD)

= 3.84 ÷ 1.83

2.1x

* Primary Listing of Sorrento Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sorrento Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Sorrento Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sorrento Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

8STN Future Performance

 How is Sorrento Therapeutics expected to perform in the next 1 to 3 years based on estimates from 3 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sorrento Therapeutics expected to grow at an attractive rate?
  • Sorrento Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Sorrento Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Sorrento Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:8STN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:8STN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 3 Analysts 47.1%
DB:8STN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 3 Analysts 46.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:8STN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:8STN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 805 76 1
2022-12-31 397 112 2
2021-12-31 230 -75 2
2020-12-31 112 -137 3
2019-12-31 40 -169 3
DB:8STN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 21 -112 -204
2018-09-30 35 -112 -105
2018-06-30 152 -104 -60
2018-03-31 153 -101 0
2017-12-31 152 -99 9
2017-09-30 135 -71 -57
2017-06-30 16 -80 -39
2017-03-31 12 -73 -68
2016-12-31 8 -71 -61
2016-09-30 5 -71 -67
2016-06-30 4 -67 -83
2016-03-31 5 -53 -51

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sorrento Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Sorrento Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:8STN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below

All data from Sorrento Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8STN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.42 0.42 0.42 1.00
2022-12-31 0.61 0.61 0.61 1.00
2021-12-31 -0.12 -0.12 -0.12 1.00
2020-12-31 -0.80 -0.71 -0.88 3.00
2019-12-31 -1.31 -1.17 -1.43 3.00
DB:8STN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.92
2018-09-30 -1.10
2018-06-30 -0.70
2018-03-31 0.00
2017-12-31 0.13
2017-09-30 -0.89
2017-06-30 -0.66
2017-03-31 -1.28
2016-12-31 -1.21
2016-09-30 -1.47
2016-06-30 -2.09
2016-03-31 -1.37

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sorrento Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Sorrento Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sorrento Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

8STN Past Performance

  How has Sorrento Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sorrento Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sorrento Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Sorrento Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sorrento Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Sorrento Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sorrento Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:8STN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 21.19 -203.54 69.74
2018-09-30 34.67 -105.32 51.64
2018-06-30 152.48 -60.05 41.75
2018-03-31 153.23 -0.38 38.91
2017-12-31 151.86 9.13 40.80
2017-09-30 135.47 -57.17 40.53
2017-06-30 15.80 -39.22 35.58
2017-03-31 12.04 -68.34 31.61
2016-12-31 8.15 -60.92 24.22
2016-09-30 5.47 -66.54 24.11
2016-06-30 4.33 -83.37 23.56
2016-03-31 4.60 -51.02 22.41
2015-12-31 4.59 -45.81 21.76
2015-09-30 4.05 -30.84 12.90
2015-06-30 4.22 -37.51 10.05
2015-03-31 3.83 -35.00 9.33
2014-12-31 3.83 -34.66 9.99
2014-09-30 3.13 -37.45 10.17
2014-06-30 1.94 -33.20 9.31
2014-03-31 1.30 -29.48 8.45
2013-12-31 0.46 -21.91 6.32
2013-09-30 0.48 -12.37 4.47
2013-06-30 0.53 -10.26 3.90
2013-03-31 0.61 -6.46 2.64
2012-12-31 0.58 -4.85 1.61
2012-09-30 0.59 -3.85 1.07
2012-06-30 0.55 -3.31 0.80 -1.22

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sorrento Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sorrento Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sorrento Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sorrento Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sorrento Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

8STN Health

 How is Sorrento Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sorrento Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sorrento Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sorrento Therapeutics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Sorrento Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sorrento Therapeutics Company Filings, last reported 3 months ago.

DB:8STN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 207.50 233.29 159.04
2018-09-30 223.56 173.77 135.74
2018-06-30 259.47 17.71 47.11
2018-03-31 240.87 7.10 24.70
2017-12-31 206.61 5.21 20.87
2017-09-30 102.29 26.98 39.21
2017-06-30 96.20 26.54 54.34
2017-03-31 62.11 26.08 35.18
2016-12-31 86.50 47.32 83.50
2016-09-30 72.49 5.65 67.72
2016-06-30 135.23 6.87 133.13
2016-03-31 88.96 8.06 67.00
2015-12-31 140.94 9.23 136.40
2015-09-30 146.79 10.37 123.45
2015-06-30 91.25 11.48 51.70
2015-03-31 100.00 12.19 60.50
2014-12-31 108.71 12.15 71.90
2014-09-30 70.99 12.10 44.27
2014-06-30 78.02 12.05 50.16
2014-03-31 59.15 12.00 29.95
2013-12-31 66.81 4.81 31.67
2013-09-30 30.88 4.79 6.43
2013-06-30 5.77 0.83 5.75
2013-03-31 10.32 0.88 9.64
2012-12-31 6.20 0.00 5.09
2012-09-30 7.35 0.00 6.45
2012-06-30 8.50 0.00 7.63
  • Sorrento Therapeutics's level of debt (112.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (7.3% vs 112.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sorrento Therapeutics has sufficient cash runway for 1.2 years based on current free cash flow.
  • Sorrento Therapeutics has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 29% each year.
X
Financial health checks
We assess Sorrento Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sorrento Therapeutics has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

8STN Dividends

 What is Sorrento Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sorrento Therapeutics dividends.
If you bought €2,000 of Sorrento Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sorrento Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sorrento Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:8STN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 3 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:8STN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sorrento Therapeutics has not reported any payouts.
  • Unable to verify if Sorrento Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sorrento Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sorrento Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Sorrento Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sorrento Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sorrento Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

8STN Management

 What is the CEO of Sorrento Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Henry Ji
COMPENSATION $1,545,000
AGE 54
TENURE AS CEO 6.6 years
CEO Bio

Dr. Henry H. Ji, Ph.D. co-founded Sorrento Therapeutics, Inc. (STI) in January 2006 and has been its Chief Executive Officer and President since September 2012 and also has been its Chairman since August 16, 2017. Dr. Ji served as Interim Chief Executive Officer of Sorrento Therapeutics from April 2011 to September 2012, Chief Scientific Officer since November 2008 until September 2012 and Secretary since September 21, 2009 until June 2011. He has more than 18 years of biotechnology and biopharmaceutical experience. In 2002, he founded BioVintage, Inc. and has served as its President since 2002. From 2001 to 2002, Dr. Ji served as Vice President of CombiMatrix Corporation. During his tenure at CombiMatrix, Dr. Ji was responsible for strategic technology alliances with biopharmaceutical companies. From 1999 to 2001, he served as Director of Business Development and in 2001 as Vice President of Stratagene Corporation (later acquired by AgilentTechnologies, Inc.) where he was responsible for novel technology and product licensing and development. In 1997, Dr. Ji co-founded Stratagene Genomics, Inc., a wholly owned subsidiary of Stratagene Corporation and served as its President and Chief Executive Officer from its founding until 1999. He has been a Director of Sorrento Therapeutics, Inc. since January 2006. He served as a Director of NantKwest, Inc. from December 2014 to December 31, 2015. He served as a Director at Quikbyte Software, Inc. since September 21, 2009. He is the holder of several issued and pending patents in the life science research field and is the sole inventor of STI’s intellectual property. Dr. Ji has a Ph.D. in Animal Physiology from the University of Minnesota and a B.S. in Biochemistry from the Fudan University.

CEO Compensation
  • Henry's compensation has been consistent with company performance over the past year.
  • Henry's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Sorrento Therapeutics management team in years:

1.6
Average Tenure
52
Average Age
  • The average tenure for the Sorrento Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Henry Ji

TITLE
Co-Founder
COMPENSATION
$2M
AGE
54
TENURE
6.6 yrs

Jerry Zeldis

TITLE
Chief Medical Officer & President of Clinical Development
COMPENSATION
$464K
AGE
68
TENURE
2.7 yrs

George Ng

TITLE
Corporate Secretary
COMPENSATION
$688K
AGE
44

Jiong Shao

TITLE
Executive VP & CFO
AGE
50
TENURE
1.1 yrs

Deborah Telman

TITLE
Senior Vice President & General Counsel
TENURE
1.3 yrs

Alexis Nahama

TITLE
Vice President of Corporate Development
TENURE
1.6 yrs

Bill Farley

TITLE
Vice President of Sales & Business Development
TENURE
1.6 yrs

Gunnar Kaufmann

TITLE
Senior VP of Immunotherapy and Head of Research & Global Partnerships
TENURE
1.6 yrs
Board of Directors Tenure

Average tenure and age of the Sorrento Therapeutics board of directors in years:

1.6
Average Tenure
55
Average Age
  • The average tenure for the Sorrento Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Richard Lerner

TITLE
Chairman of Scientific Advisory Board
AGE
80

Henry Ji

TITLE
Co-Founder
COMPENSATION
$2M
AGE
54
TENURE
1.7 yrs

Kim Janda

TITLE
Independent Director
COMPENSATION
$132K
AGE
60
TENURE
7 yrs

Alexander Wu

TITLE
Director
COMPENSATION
$124K
AGE
54
TENURE
2.7 yrs

Dave Lemus

TITLE
Independent Director
COMPENSATION
$74K
AGE
55
TENURE
1.6 yrs

Jaisim Shah

TITLE
Lead Independent Director
COMPENSATION
$137K
AGE
58
TENURE
0.8 yrs

Dorman Followwill

TITLE
Independent Director
COMPENSATION
$74K
AGE
55
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. Sep 18 Sell Ally Bridge Group Company 12. Sep 18 13. Sep 18 -297,568 €4.33 €-1,278,219
X
Management checks
We assess Sorrento Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sorrento Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

8STN News

Simply Wall St News

8STN Company Info

Description

Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. The company also develops CD38 Directed chimeric antigen receptor T-cell therapy (CAR-T) for the treatment of multiple myeloma, as well as for amyloidosis and graft-versus-host diseases; carcinoembryonic antigen CAR-T cell therapy for the treatment of liver metastases of pancreatic cancer; and various human antibodies. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

Details
Name: Sorrento Therapeutics, Inc.
8STN
Exchange: DB
Founded: 2006
$391,687,028
114,711,910
Website: http://www.sorrentotherapeutics.com
Address: Sorrento Therapeutics, Inc.
4955 Directors Place,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM SRNE Common Stock Nasdaq Capital Market US USD 22. Sep 2009
DB 8STN Common Stock Deutsche Boerse AG DE EUR 22. Sep 2009
LSE 0L85 Common Stock London Stock Exchange GB USD 22. Sep 2009
Number of employees
Current staff
Staff numbers
382
Sorrento Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 21:49
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/03/15
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.